Black Diamond Therapeutics (BDTX) Invested Capital (2018 - 2025)
Black Diamond Therapeutics' Invested Capital history spans 6 years, with the latest figure at $112.2 million for Q4 2025.
- For Q4 2025, Invested Capital rose 34.73% year-over-year to $112.2 million; the TTM value through Dec 2025 reached $112.2 million, up 34.73%, while the annual FY2025 figure was $112.2 million, 34.73% up from the prior year.
- Invested Capital reached $112.2 million in Q4 2025 per BDTX's latest filing, down from $126.2 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $280.8 million in Q1 2021 to a low of $83.3 million in Q4 2024.
- Average Invested Capital over 3 years is $150.8 million, with a median of $126.2 million recorded in 2025.
- Peak YoY movement for Invested Capital: plummeted 33.15% in 2021, then skyrocketed 35.67% in 2025.
- A 3-year view of Invested Capital shows it stood at $218.9 million in 2021, then crashed by 61.96% to $83.3 million in 2024, then skyrocketed by 34.73% to $112.2 million in 2025.
- Per Business Quant, the three most recent readings for BDTX's Invested Capital are $112.2 million (Q4 2025), $126.2 million (Q3 2025), and $132.6 million (Q2 2025).